Cytosorbents’ Earnings Call Balances Progress and Risk

Cytosorbents Corp ((CTSO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Cytosorbents’ latest earnings call struck a cautiously optimistic tone, balancing record core product sales, robust margins, and clear cost-cutting plans with persistent losses, a tight cash position, and lingering FDA uncertainty. Management leaned on growing international traction and clinical validation to argue the story is improving, even as near‑term financial and regulatory risks keep investors on edge.

Moderate Top-Line Growth and Record Core Sales

Full year 2025 revenue rose 4% to $37.1 million, marking a new high for core product sales despite currency headwinds that left growth flat on a constant-currency basis. Management framed this as evidence of underlying demand resilience in a challenging macro and reimbursement environment.

International Diversification Offsets German Weakness

Direct sales outside Germany climbed 13% to $8.6 million and distributor sales rose 11.4% to $16.5 million, with these channels now contributing about 68% of total revenue. The company stressed that this growing international mix is reducing reliance on any single market and should help smooth volatility.

High and Improving Gross Margins

Gross margin for the full year reached 71% and improved further to 74% in the fourth quarter, driven largely by manufacturing efficiencies. Management reiterated that margins in the low‑70% range are sustainable, giving Cytosorbents a strong base to eventually leverage into profitability.

Cost Controls and Path to Cash Flow Breakeven

Operating loss improved 10% to $14.7 million in 2025 and adjusted EBITDA loss narrowed 9% to $10.5 million, helped by expense discipline. The company laid out a goal of reaching operating cash flow breakeven in the second half of 2026, assuming successful cost reductions and normalization of working capital.

DrugSorb‑ATR Gains Clinical Traction Amid FDA Delays

The STAR‑T randomized trial, published in JTCVS, showed that DrugSorb‑ATR was safe and reduced bleeding severity in high‑risk CABG patients, strengthening the product’s clinical case. Cytosorbents is in ongoing interactive dialogue with the FDA after an appeal confirmed no device safety concerns and narrowed the remaining issues for resubmission.

Product Innovation and Growing Installed Base

PuriFi pump placements have surpassed 100 units worldwide, expanding access and supporting earlier intervention with a razor‑razorblade model for future disposable revenue. The company also launched its HotSwap exchange innovation, received positive feedback at ISICEM, and highlighted that more than 300,000 CytoSorb treatments have now been delivered across 70 countries.

R&D Pullback and Tighter Expense Management

Operating expenses were roughly flat at $41.2 million for the year, but included a $2.5 million reduction in R&D tied to lower clinical and project spending. Management is selectively increasing SG&A to support regulatory and commercial priorities while workforce restructuring is intended to lower ongoing cash burn.

German Restructuring Weighs on Revenue

Sales in Germany fell 10% to $11.8 million in 2025, reflecting disruption from a deliberate overhaul of the German sales organization. Management described the turnaround as gradual and expects improvement to show up over 2026, but acknowledged this key market will remain a drag in the near term.

Widening Net and Adjusted Losses

Adjusted net loss for 2025 widened to $14.2 million, or $0.23 per share, compared with $12.7 million a year earlier, underscoring that profitability is still some distance away. In the fourth quarter, adjusted net loss expanded to $4.3 million, or $0.07 per share, versus $1.7 million, or $0.03 per share, in the prior-year period.

Soft Q4 and Profitability Pressures

Fourth quarter 2025 revenue edged up just 1% year over year to $9.2 million, but declined 8% on a constant-currency basis, reflecting both FX effects and operational headwinds. Q4 operating loss increased to $4.6 million and adjusted EBITDA loss widened to $3.2 million, highlighting that near‑term profitability remains under pressure.

Thin Cash Cushion and Working Capital Drag

Cytosorbents ended the year with $7.8 million in cash, cash equivalents, and restricted cash, down from $9.1 million the prior quarter, despite taking on $2.5 million in new debt. Net operating cash burn in Q4 was $3.8 million, with about $1.9 million of working capital build, including higher inventory and receivables, contributing to the outflow.

Regulatory Setback Clouds Timing for DrugSorb‑ATR

The initial De Novo submission for DrugSorb‑ATR was denied, representing a meaningful regulatory setback for a key growth driver. While the appeal removed safety concerns and narrowed FDA questions, management conceded that the timing and final requirements for resubmission remain uncertain and hinge on ongoing agency discussions.

PuriFi in Investment Mode With Limited Revenue

The PuriFi platform is being positioned as a long-term consumables business, similar to a printer and cartridge model, but is not yet contributing materially to revenue. With more than 100 pumps placed, the company continues to subsidize or finance placements, accepting near‑term margin pressure for potential recurring sales later.

Restructuring Charges Add to Near-Term Volatility

Fourth quarter results included a $0.5 million restructuring charge, split between about $400,000 of cash severance and $100,000 of noncash items, reflecting recent workforce reductions. Management argued these actions should support future savings, even as they contribute to short-term noise in reported expenses.

Guidance and Strategic Priorities Ahead

Looking ahead, Cytosorbents is targeting operating cash‑flow breakeven in the back half of 2026, expecting cash burn to ease as working capital normalizes in early 2026 and cost actions take hold. The company aims to sustain gross margins in the 71–74% range while growing revenue beyond 2025 levels by fixing Germany, expanding international channels, advancing PuriFi, and moving DrugSorb‑ATR toward an eventual FDA resubmission.

Cytosorbents’ call painted a story of a medtech company with strong clinical data, high margins, and expanding international reach, but also one navigating restructuring, regulatory uncertainty, and a thin cash buffer. For investors, the stock now hinges on management’s ability to execute the German turnaround, convert PuriFi and DrugSorb‑ATR into real revenue, and deliver on the 2026 cash‑flow breakeven target.